ResultsIQ

ResultsIQ › Latest results › Morepen Laboratories Limited

Morepen Laboratories Limited Q3 FY26 results deck summary

NSE: MOREPENLAB · BSE: 500288

Results deck of 10 Feb 2026, summarised by AI from the filing.

Q3 FY26 standalone revenue ₹462 cr, EBITDA ₹46 cr and PAT ₹23 cr; 9M FY26 Medical Devices revenue ₹464 cr (+18%)

Key takeaways

  1. Standalone revenue ₹462 cr in Q3 FY26 (Q2 FY26: ₹374 cr, +23%)
  2. Standalone EBITDA ₹46 cr in Q3 FY26 (Q2 FY26: ₹33 cr, +41%)
  3. Standalone PAT ₹23 cr in Q3 FY26 (Q2 FY26: ₹13 cr, +77%)
  4. Medical Devices Revenue ₹464 cr in 9M FY26 (9M FY25: ₹394 cr, +18%)
  5. Pharma Business Revenue ₹767 cr in 9M FY26 (9M FY25: ₹791 cr, -3%)

Original filing on BSE

Morepen Laboratories Limited Q1 FY27 results

As filed: Revenue ₹570 cr (+34% year on year), EBITDA ₹82.5 cr (+230% year on year), PAT ₹56.4 cr (+300% year on year), EBITDA margin 14.5% (+860 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹485 cr (+4% year on year), EBITDA ₹24.5 cr (−42% year on year), PAT ₹15.7 cr (−21% year on year), EBITDA margin 5.1% (−397 bps). Score 24 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 397 bps year on year. Other income 36% of PBT. Consolidated profit -21% but standalone +68%. Profit fell 43% from last quarter. Share price after the results: +21.0% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹484 cr (+7% year on year), EBITDA ₹46.3 cr (+29% year on year), PAT ₹27.5 cr (+2% year on year), EBITDA margin 9.6% (+162 bps). Score 46 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 162 bps year on year. Profit fell 33% from last quarter. Share price after the results: +1.9% in 30 days (Nifty 500: −7.5%).
  • Q2 FY26: Revenue ₹412 cr (−6% year on year), EBITDA ₹30.0 cr (−32% year on year), PAT ₹41.0 cr (−57% year on year), EBITDA margin 7.3% (−276 bps). Score 17 of 100, Below trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 276 bps year on year. Tax rate 11%. Consolidated profit +17% but standalone -56%. Revenue fell 3% from last quarter. Share price after the results: −10.9% in 28 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹425 cr (−7% year on year), EBITDA ₹25.0 cr (−52% year on year), PAT ₹11.0 cr (−69% year on year), EBITDA margin 5.9% (−555 bps). Score 16 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 555 bps year on year. Revenue fell 9% from last quarter. Share price after the results: −12.8% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹466 cr (+10% year on year), EBITDA ₹42.0 cr (−14% year on year), PAT ₹20.0 cr (−29% year on year), EBITDA margin 9.0% (−257 bps). Score 29 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 257 bps year on year. Profit fell 26% from last quarter. Share price after the results: +11.6% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹453 cr (+2% year on year), EBITDA ₹36.0 cr (−28% year on year), PAT ₹27.0 cr (−16% year on year), EBITDA margin 8.0% (−329 bps). Score 13 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 329 bps year on year. Profit fell 23% from last quarter.
  • Q2 FY25: Revenue ₹438 cr (+4% year on year), EBITDA ₹44.0 cr (+29% year on year), PAT ₹35.0 cr (+67% year on year), EBITDA margin 10.1% (+199 bps). Score 68 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Morepen Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.